Format

Send to

Choose Destination
Breast Cancer Res Treat. 2018 Feb;168(1):69-77. doi: 10.1007/s10549-017-4550-8. Epub 2017 Nov 11.

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.

Author information

1
National Surgical Adjuvant Breast and Bowel Project (NSABP) (NSABP Legacy trials are now a part of the NRG Oncology portfolio), Pittsburgh, PA, USA. terry.mamounas@orlandohealth.com.
2
UF Health Cancer Center at Orlando Health, 1400 S., Orange Avenue, MP 700, Orlando, FL, 32806, USA. terry.mamounas@orlandohealth.com.
3
NRG Oncology and the University of Pittsburgh, Pittsburgh, PA, USA.
4
National Surgical Adjuvant Breast and Bowel Project (NSABP) (NSABP Legacy trials are now a part of the NRG Oncology portfolio), Pittsburgh, PA, USA.
5
Yonsei University College of Medicine, Seoul, South Korea.
6
Genomic Health, Inc, Redwood City, CA, USA.
7
Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA, USA.

Abstract

BACKGROUND:

The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen.

METHODS:

The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients. Tamoxifen for 5 years was also given to patients > 50 years and those < 50 years with ER+ and/or progesterone receptor-positive (PR+) tumors. The present study includes 1065 ER-positive, tamoxifen-treated patients with RS assessment. Median follow-up time was 11.2 years.

RESULTS:

In univariate analyses, RS was a significant predictor of outcome. In multivariate analyses, RS remained a significant independent predictor of outcome beyond clinico-pathologic factors, age, and type of surgery (p < 0.001). In the study population (n = 1065), the disease-free survival (DFS) hazard ratio (HR) with adding P to AC was 0.87 (95% CI 0.72-1.05; p = 0.14). RS was not a significant predictor of P benefit: for DFS, HRs for adding P to AC in RS low, intermediate, and high subgroups were 1.01 (95% CI 0.69-1.47; p = 0.99), 0.84 (95% CI 0.62-1.14; p = 0.26), and 0.81 (95% CI 0.60-1.10; p = 0.21), respectively (interaction p = 0.64). Similar findings were observed for the other study endpoints.

CONCLUSIONS:

RS maintains significant prognostic impact in ER-positive, node-positive patients treated with adjuvant chemotherapy plus tamoxifen. However, RS did not significantly predict benefit from adding paclitaxel to AC chemotherapy. (Trial Registration: PDQ: NSABP-B-28).

KEYWORDS:

Breast cancer; Node-positive; Prognosis and prediction; Recurrence score

PMID:
29128898
PMCID:
PMC5996978
DOI:
10.1007/s10549-017-4550-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center